Drug intelligence / Profile preview

Semical Gel-B Cross

Development stage: Unknown
Lead developer: Semical Biosurgery
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Intraarticular

Overview

**Semical Gel-B Cross** is a cross-linked, bio-fermented sodium hyaluronate viscoelastic solution designed as a viscosupplement for intra-articular injection to treat knee pain due to osteoarthritis. It mimics synovial fluid, providing lubrication and shock absorption to improve joint function, reduce pain, and remain in tissues longer with a single injection of 2-3 mL (typically 60-90 mg). Developed by Semical Biosurgery in Turkey, it features advanced thixotropic properties and non-animal origin, with ongoing clinical evaluation in phase-like trials for safety and efficacy.[1][2][3]

Brand names: Semical Gel-B CrossSEMICAL® intra-articular Gel-B Cross
Other names: Sectalon Gel-B Cross

Beyond the preview

Go deeper on Semical Gel-B Cross.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Semical Gel-B Cross.

Explore the full profile